Skip Navigation LinksHematology

​​​​​​​​​​​​​​​​Hematology Trials


Cancer Control/Prevention

U10055: Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-Up

NHL​BI-​MDS​​:  The National Myelodysplastic Syndromes Natural History Study​

Lymphoma, Hodgkin's​


Lymphoma, Non-Hodgkin's

​​UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

​​Diffuse Large B-cell​

RU051417I: Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Follicular

​Mantle Cell


Plasmablastic

Lymphoma, Hodgkin's


Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

​Chronic Myelomonocytic Leukemia

​CONNECT MDS AML: ​The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry


Myelodysplastic Syndrome Chronic

Multiple Myeloma

E1A11:  Randomized Phase III Trial of Bo​rtezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Sy​mptomatic Multiple Myeloma (ENDURANCE)

S12​11​​: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)​​

Insight (NSMM-5001): ​Global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study